Source - RNS
RNS Number : 8890I
Allergy Therapeutics PLC
05 September 2016
 



5 September 2016

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Notice of Preliminary Results

 

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its preliminary results for the twelve-month period ended 30 June 2016 on Monday 26 September 2016.

 

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a presentation and conference call for analysts on the day of results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[email protected]

 

Note to editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOREAFNLEDKKEAF

Related Charts

Allergy Therapeutics (AGY)

+1.25p (+5.21%)
delayed 18:15PM